Nomura reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report report published on Tuesday morning, AnalystRatings.com reports. Nomura currently has a $37.00 price target on the stock.
“Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future.”,” the firm’s analyst commented.
VYGR has been the topic of several other reports. BidaskClub lowered Voyager Therapeutics from a hold rating to a sell rating in a report on Wednesday, August 7th. Wedbush raised their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the company an outperform rating in a report on Tuesday, June 18th. Morgan Stanley raised their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an equal weight rating in a report on Friday, July 12th. Finally, HC Wainwright reiterated a buy rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research note on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $27.50.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $1.17. Voyager Therapeutics had a negative return on equity of 82.98% and a negative net margin of 106.23%. The company had revenue of $46.09 million for the quarter, compared to analyst estimates of $5.25 million. On average, analysts forecast that Voyager Therapeutics will post -2.67 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of Voyager Therapeutics by 4.2% during the 4th quarter. Bank of New York Mellon Corp now owns 88,459 shares of the company’s stock valued at $831,000 after buying an additional 3,543 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Voyager Therapeutics by 23.1% during the 4th quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock valued at $2,700,000 after buying an additional 53,888 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Voyager Therapeutics by 211.0% during the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after buying an additional 7,217 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Voyager Therapeutics by 449.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at approximately $235,000. Institutional investors and hedge funds own 73.92% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: What is a Market Correction?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.